Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib plus imatinib in advanced desmoid tumor (Phase 1b/2a, Korea)
KCT0003449Phase 2Completed
- Sponsor
- Boryung
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vactosertib and imatinib in aggressive fibromatosis (AF), sponsored by Boryung. Primary endpoints: Safety and tolerability of vactosertib + imatinib, Pharmacokinetics of vactosertib in combination with imatinib and 1 more. Started Apr 2019; status: completed.
02
Drugs
vactosertibimatinib
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on KCT0003449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003449.